Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with T2D
Hydroxyureas efficacy varies among patients, and gene therapies, though effective, are limited by issues of accessibility and affordability
Cardiovascular disease is the leading cause of death in patients with CKD
Nonetheless, the magnitude of weight reduction observed at higher doses is notable given that achieving substantial weight loss in individuals with type 2 diabetes has historically been more difficult than in those with obesity alone, partly due to the metabolic effects of the condition itself and certain antidiabetic medications
Ferrari, G
the chromatogram trace itself matters at least as much as the headline percentage
US$ 29.59
US$ 23.24
US$ 25.29
